Albumin Market Analysis

Albumin Segmentation

Type (Recombinant Albumin, Human Serum Albumin, Bovine Albumin)

The human serum albumin segment is estimated to hold over 55% share of the albumin market in the year 2037. The segment growth is due to a rise in the number of new drug development followed by higher expenditure in the R&D in the pharmaceutical industry. Within the next five years, through 2026, more than three hundred new medications are scheduled to be introduced onto the market. This is a considerable rise above the preceding decade’s average. Moreover, globally around USD 196 billion is expected to be invested in the research of new drugs. Human serum albumin is often used in the formulation of drugs to improve their stability, solubility, and bioavailability. Human serum albumin increases drug solubility, especially for poorly water-soluble compounds. Moreover, it also acts as a stabilizer, preventing degradation or aggregation of drug molecules.

Application (Drug Formulation & Vaccines, Therapeutics, Research)

The therapeutics segment is expected to accumulate a notable revenue share of around 45% in the year 2037. Rising cases of severe burns and other traumas will drive the growth of the segment. Severe burns lead to extensive fluid loss and dehydration. Albumin is used as a plasma expander to restore and maintain intravascular volumes, and it is also used for maintaining oncotic pressure restoration.

Our in-depth analysis of the global market includes the following segments: